The primary objective of this study was to estimate a clinically significant and quantifiable change in functional disability to identify treatment responders in a clinical trial of cognitive-behavioral therapy (CBT) for youth with juvenile fibromyalgia (JFM). The second objective was to examine whether baseline functional disability (Functional Disability Inventory), pain intensity, depressive symptoms (Children's Depression Inventory), coping self-efficacy (Pain Coping Questionnaire), and parental pain history predicted treatment response in disability at 6-month follow-up. Participants were 100 adolescents (11-18 years of age) with JFM enrolled in a recently published clinical trial comparing CBT to a fibromyalgia education (FE) intervention. Patients were identified as achieving a clinically significant change in disability (ie, were considered treatment responders) if they achieved both a reliable magnitude of change (estimated as a P7.8-point reduction on the FDI) using the Reliable Change Index, and a reduction in FDI disability grade based on established clinical reference points. Using this rigorous standard, 40% of patients who received CBT (20 of 50) were identified as treatment responders, compared to 28% who received FE (14 of 50). For CBT, patients with greater initial disability and higher coping efficacy were significantly more likely to achieve a clinically significant improvement in functioning. Pain intensity, depressive symptoms, and parent pain history did not significantly predict treatment response. Estimating clinically significant change for outcome measures in behavioral trials sets a high bar but is a potentially valuable approach to improve the quality of clinical trials, to enhance interpretability of treatment effects, and to challenge researchers to develop more potent and tailored interventions. Ó
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Introduction
Cognitive-behavioral therapy (CBT) is an effective treatment for pediatric chronic pain conditions that significantly reduces functional disability [11, 35] , with 1 study demonstrating maintenance of improvement in disability over 6 months for adolescents with juvenile fibromyalgia (JFM) [26] . Even with large and statistically significant overall treatment effects reported in clinical trials, there is variability in outcomes for individual patients, and not all patients achieve functional improvements that are clinically meaningful [13] . Clinically meaningful or significant improvements are considered worthwhile to patients and involve a noticeable reduction in symptomatology [2, 7, 18] . To distinguish patients who achieve clinically significant improvements from those who do not, it is important to determine cut-off scores for outcome measures that represent clinically meaningful change. 
